Having withdrawn Blenrep (belantamab mafodotin-blmf) from the US market in 2022 after failing to confirm the benefit of the antibody-drug conjugate in late-line multiple myeloma, GSK plc is preparing to refile this year for use in the second-line setting based on the DREAMM-8 trial presented 2 June at the American Society of Clinical Oncology annual meeting. The company is confident that the DREAMM-7 and 8 trials together show a “consistency of treatment effect.”
ASCO: GSK Confident In DREAMM Of Returning Blenrep To Market
DREAMM-8 Trial Is Second Trial Supporting Second-Line Use
The antibody-drug conjugate, withdrawn from market for late-line use, is poised to make a return with strong results in DREAMM-7 and 8. GSK plans to refile later this year.
